Company & Sponsor Intelligence
Genentech, Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials5
Recruiting0
Completed4
Countries1
Therapeutic footprint
alzheimersmultiple_sclerosisstroke
Indexed studies
NCT03785678Tenecteplase in Stroke Patients Between 4.5 and 24 Hours
stroke · United StatesPHASE3
stroke · United StatesPHASE3
NCT02637856A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
multiple_sclerosis · United StatesPHASE3
multiple_sclerosis · United StatesPHASE3
NCT01343966A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT01723826A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT03289143A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →